Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.Please watch the video at Investors.com - The Weight-Loss ...
“I’m not concerned," he said, “that there’s some risk that that we would lose our statutory independence. “There’s very, very broad support for that set of ideas in Congress, in both political parties ...